BFC
VRTX icon

Bedel Financial Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

Bedel Financial Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed – – 924
2020
Q1 		$0 Buy
+1
New +$229 ﹤0.01% 916

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bedel Financial Consulting's VRTX Position: Q2 2020 in Review

Bedel Financial Consulting sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 1 share.

Bedel Financial Consulting first reported a position in VRTX in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 964 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • Bedel Financial Consulting reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Bedel Financial Consulting sold 1 Vertex Pharmaceuticals share in Q2 2020.
  • Bedel Financial Consulting first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Bedel Financial Consulting's Vertex Pharmaceuticals position peaked at $0 in Q1 2020.
  • 964 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Bedel Financial Consulting's 13F filing for Q2 2020, filed 14 Jul 2020.